Jazz Pharmaceuticals Rallying on Strong Outlook

Jazz Pharmaceuticals JAZZ is trading higher on the session after the company announced a better than expected 2012 outlook yesterday. The company expects to report FY 2012 adjusted EPS of $4.00 – 4.15 vs $3.40 estimate and total revenues of $465–490 million vs $462.8 million estimates. The company's CEO said "we were pleased with the strong performance of Xyrem in 2011, including nine percent year-over-year volume growth in the fourth quarter and 11 percent volume growth for the full year, as we continue to invest in this important product." Jazz Pharmaceuticals is currently trading at $45.38, up $3.92 or 9.45%.